Can-Fite BioPharma American Depositary Shares
CANF
8 hedge funds and large institutions have $518K invested in Can-Fite BioPharma American Depositary Shares in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
922% more capital invested
Capital invested by funds: $50.7K → $518K (+$467K)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more funds holding
Funds holding: 4 → 8 (+4)
0% more ownership
Funds ownership: 0% → 0% (+0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$364K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
+$22.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$18.4K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$3.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$26K |
| 2 |
Morgan Stanley
New York
|
-$11.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10.3K |
CANF Hedge Fund Activity: Q2 2020 in Review
8 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q2 2020, worth a combined $518K — up 922% from $50.7K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CANF positions and 1 closed out — a net gain of 4 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was CVI Holdings, opening a new position worth an estimated $364K. The largest seller was Citadel Advisors, exiting entirely with an estimated $26K sold.
- 8 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q2 2020, up from 4 in Q1 2020.
- Funds reported $518K of Can-Fite BioPharma American Depositary Shares stock for Q2 2020, up 922% quarter-over-quarter.
- 5 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q2 2020 and 1 closed out, a net change of +4 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q2 2020 was CVI Holdings, an estimated $364K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q2 2020 was Citadel Advisors, an estimated $26K sold.
Based on aggregated 13F filings for Q2 2020.